Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma

NCT00688415 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00688415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00688415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
November 7, 2008
Completion date
November 30, 2010
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, lymphoma